McCall McPhersonFounder, Modern Thyroid Clinic.

GLPs: Revolutionizing Medicine Beyond Weight Loss #shorts

5 Sept 2026 · 1 min

Watch on YouTube

0:43

In this short video, McCall McPherson explains his emerging focus on using glucagon‑like peptide (GLP) medications for patients with chronic hypothyroidism who have become metabolically resistant. He describes how years of untreated or undertreated hypothyroidism lead to insulin and leptin resistance, creating a state of metabolic dysfunction that does not resolve simply by normalising thyroid hormone levels. McPherson began prescribing GLP agents primarily for weight loss, but observed that patients continued the therapy for broader metabolic improvements. He argues that the true significance of GLP drugs lies beyond weight reduction, predicting they will become one of the most transformative advances in medicine during his lifetime.

Chapters

So, this is my other passion project. I didn't think I'd ever be as passionate about anything outside of thyroid, but I am. I started using GLPs in my patients because they're metabolically resistant. Like, we lose our metabolism with years and years of hypothyroidism. We become insulin resistant, leptin resistant, metabolically dysfunctional. And that doesn't unravel immediately just when I fix your thyroid hormones, because you have to unwind those years, decades— Right. Of that dysfunction. So, I used GLPs initially for weight loss. And what I found was it's great. People start it for weight loss, they continue it for entirely different reasons. And I think this is the biggest thing that will happen in my lifetime in medicine, these medications, and it has nothing to do with weight loss.